Oncology Hematology Associates | Springfield, MO
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion:
Exclusion
Primary purpose
Allocation
Interventional model
Masking
550 participants in 2 patient groups
Loading...
Central trial contact
Amgen Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal